AbbVie sheds assets as it heads for tie-up with Botox maker
Nestle buys Zenpep, while AstraZeneca gets back its brazikumab experimental drug
27 January 2020 - 17:29
Zurich — US drugmaker AbbVie’s $63bn tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.
AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19bn-per-year arthritis drug Humira, the world’s best-selling medicine that is advancing towards US patent expiration...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.